obÌåÓý

Pregnant Women RSV Vaccination Coverage

Weekly RSV vaccination coverage estimates for pregnant women 18–49 years are based on electronic health record (EHR) data from the Vaccine Safety Datalink (VSD), a collaboration between obÌåÓý's Immunization Safety Office and multiple integrated health care organizations.*

The denominator includes those who reached at least 32 weeks' gestation since September 1, 2024.^† The numerator includes those who have received an RSV vaccine during pregnancy as of the week ending date.^‡ Pregnant women are not removed from the numerator or denominator when the pregnancy ends. Cumulative vaccination coverage for one week may be lower than cumulative coverage for a previous week due to the addition of pregnant women in the denominator.^§ Additionally, no requirements for length of enrollment in a VSD site are applied, and vaccinations given outside of a VSD site might not be included.^±

• Figure 5A. Percent of Pregnant Women Ages 18–49 Years Vaccinated with RSV Vaccine Overall and by Race and Ethnicity. Data Source: Vaccine Safety Datalink.
  
• Figure 5B. Percent of Pregnant Women Ages 18–49 Years Vaccinated with RSV Vaccine by Week and Race and Ethnicity. Data Source: Vaccine Safety Datalink.
  

^{Note: Data from the 2023–24 RSV season have been archived and can be accessed using the following link: 2023-24 RSV Vaccination Coverage, Pregnant Women. Archived 2023–24 season data are based on 8 reporting sites whereas data reported during 2024–25 season include 10 reporting sites.}

^{*Naleway AL, Crane B, Irving SA, et al. Ther Adv Drug Saf. 2021, Jun 14.}

^{†Pregnant women who were past the recommended window of 32-36 week's gestation prior to September 1, 2024, were removed from the denominator. The denominator may include pregnant women 32–36 weeks of pregnancy as of September 1, 2024 or later, who received an RSV vaccine during a previous pregnancy. These pregnant women are therefore not eligible for another RSV vaccine this season/pregnancy; however, their infants would be eligible to receive nirsevimab.}

^{‡Vaccinations may have been administered outside the recommended window of 32–36 weeks gestation. Frequently Asked Questions About RSV Vaccine for Pregnant Women | obÌåÓý}

^{§The coverage estimate for any given week may change as the season progresses.}

^{±Estimates presented here might underestimate RSV vaccination coverage among women enrolled in the VSD sites. For example, in an analysis conducted after the 2023–24 season in August 2024 that allowed for more time to capture vaccine administrations in electronic health records and was restricted to women with continuous enrollment at a VSD site from September 22, 2023–January 31, 2024, coverage increased from 17.8% to 30.5%.}